Glycosmedia Weekly Diabetes News Update
View this email in your browser

Platinum Sponsors:

Boehringer Ingelheim Lilly

Gold Sponsors:

Novo Nordisk

AstraZeneca

Silver Sponsors:
 

Abbott Diabetes Care

Ericas

Glycosmedia Weekly Diabetes News - 08/28/2020

Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis

NAFLD prevalence in patients with type 1 diabetes is considerable and is highly dependent on the specific diagnostic modality and NAFLD definition used. These data are helpful in directing actions to standardize NAFLD diagnosis, which will help defining contributing mechanisms and outcomes (Journal of Clinical Endocrinology & Metabolism)


Dietary strategies to manage diabetes and glycemic control in youth and young adults with youth‐onset type 1 and type 2 diabetes

For several dietary strategies, more frequent use over time was related to lower A1c in youth‐onset type 1 and type 2 diabetes, suggesting these strategies can likely support diabetes management for this population (Pediatric Diabetes)


Efficacy of once-weekly semaglutide vs empagliflozin added to metformin in type 2 diabetes: patient-level meta-analysis

This indirect comparison suggests that OW semaglutide 1 mg provides superior reductions in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy (Journal of Clinical Endocrinology & Metabolism)


Diabetes distress and HbA1c in racially/ethnically and socioeconomically diverse youth with type 1 diabetes

Diabetes distress is elevated in a younger population of children with T1D who are from racial/ethnic minority backgroundsor have markers of lower SES (Pediatric Diabetes)


Autoantibodies against zinc transporter 8 further stratify the autoantibody-defined risk for type 1 diabetes in a general population of schoolchildren and have distinctive isoform binding patterns in different forms of autoimmune diabetes

Zinc transporter 8 autoantibodies are useful markers for prediction of type 1 diabetes in a general population, further stratifying the risk of progression in autoantibody-positive children (Diabetic Medicine)


Share
Tweet
Forward
+1
Share
Please visit the Glycosmedia website for more features and information, including:

Journal Watch
Comment on recently published papers written by the medical editors of Glycosmedia.

Diabetes Updates
Updates written by Professor Steve Bain (Diabetologist) and Dr. Mark Freeman (Diabetologist).

Book and Product Reviews
A selection of book and product reviews written by the contributing editors of Glycosmedia.
The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Glycosmedia complies with the HONcode standard for trustworthy health information: verify here.


Copyright © 2020 Glycosmedia Partnership

Our mailing address is:
Glycosmedia
9 Woodburn Drive
West Cross
Swansea, West Glamorgan SA3 5TZ
United Kingdom

Add us to your address book


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp